771 related articles for article (PubMed ID: 11176842)
1. Risk of new vertebral fracture in the year following a fracture.
Lindsay R; Silverman SL; Cooper C; Hanley DA; Barton I; Broy SB; Licata A; Benhamou L; Geusens P; Flowers K; Stracke H; Seeman E
JAMA; 2001 Jan; 285(3):320-3. PubMed ID: 11176842
[TBL] [Abstract][Full Text] [Related]
2. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group.
Harris ST; Watts NB; Genant HK; McKeever CD; Hangartner T; Keller M; Chesnut CH; Brown J; Eriksen EF; Hoseyni MS; Axelrod DW; Miller PD
JAMA; 1999 Oct; 282(14):1344-52. PubMed ID: 10527181
[TBL] [Abstract][Full Text] [Related]
3. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators.
Ettinger B; Black DM; Mitlak BH; Knickerbocker RK; Nickelsen T; Genant HK; Christiansen C; Delmas PD; Zanchetta JR; Stakkestad J; Glüer CC; Krueger K; Cohen FJ; Eckert S; Ensrud KE; Avioli LV; Lips P; Cummings SR
JAMA; 1999 Aug; 282(7):637-45. PubMed ID: 10517716
[TBL] [Abstract][Full Text] [Related]
4. Teriparatide and raloxifene reduce the risk of new adjacent vertebral fractures in postmenopausal women with osteoporosis. Results from two randomized controlled trials.
Bouxsein ML; Chen P; Glass EV; Kallmes DF; Delmas PD; Mitlak BH
J Bone Joint Surg Am; 2009 Jun; 91(6):1329-38. PubMed ID: 19487509
[TBL] [Abstract][Full Text] [Related]
5. Mild prevalent and incident vertebral fractures are risk factors for new fractures.
Roux C; Fechtenbaum J; Kolta S; Briot K; Girard M
Osteoporos Int; 2007 Dec; 18(12):1617-24. PubMed ID: 17611706
[TBL] [Abstract][Full Text] [Related]
6. Comparison of fracture, cardiovascular event, and breast cancer rates at 3 years in postmenopausal women with osteoporosis.
Silverman SL; Delmas PD; Kulkarni PM; Stock JL; Wong M; Plouffe L
J Am Geriatr Soc; 2004 Sep; 52(9):1543-8. PubMed ID: 15341559
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: implications for the use of antiresorptive agents in the old and oldest old.
Boonen S; McClung MR; Eastell R; El-Hajj Fuleihan G; Barton IP; Delmas P
J Am Geriatr Soc; 2004 Nov; 52(11):1832-9. PubMed ID: 15507059
[TBL] [Abstract][Full Text] [Related]
8. Determinants of incident vertebral fracture in men and women: results from the European Prospective Osteoporosis Study (EPOS).
Roy DK; O'Neill TW; Finn JD; Lunt M; Silman AJ; Felsenberg D; Armbrecht G; Banzer D; Benevolenskaya LI; Bhalla A; Bruges Armas J; Cannata JB; Cooper C; Dequeker J; Diaz MN; Eastell R; Yershova OB; Felsch B; Gowin W; Havelka S; Hoszowski K; Ismail AA; Jajic I; Janott I; Johnell O; Kanis JA; Kragl G; Lopez Vaz A; Lorenc R; Lyritis G; Masaryk P; Matthis C; Miazgowski T; Gennari C; Pols HA; Poor G; Raspe HH; Reid DM; Reisinger W; Scheidt-Nave C; Stepan JJ; Todd CJ; Weber K; Woolf AD; Reeve J;
Osteoporos Int; 2003 Jan; 14(1):19-26. PubMed ID: 12577181
[TBL] [Abstract][Full Text] [Related]
9. Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk.
Boonen S; Adachi JD; Man Z; Cummings SR; Lippuner K; Törring O; Gallagher JC; Farrerons J; Wang A; Franchimont N; San Martin J; Grauer A; McClung M
J Clin Endocrinol Metab; 2011 Jun; 96(6):1727-36. PubMed ID: 21411557
[TBL] [Abstract][Full Text] [Related]
10. Risk factors associated with incident clinical vertebral and nonvertebral fractures in postmenopausal women: the Canadian Multicentre Osteoporosis Study (CaMos).
Papaioannou A; Joseph L; Ioannidis G; Berger C; Anastassiades T; Brown JP; Hanley DA; Hopman W; Josse RG; Kirkland S; Murray TM; Olszynski WP; Pickard L; Prior JC; Siminoski K; Adachi JD
Osteoporos Int; 2005 May; 16(5):568-78. PubMed ID: 15517191
[TBL] [Abstract][Full Text] [Related]
11. Vertebral fracture risk reduction with strontium ranelate in women with postmenopausal osteoporosis is independent of baseline risk factors.
Roux C; Reginster JY; Fechtenbaum J; Kolta S; Sawicki A; Tulassay Z; Luisetto G; Padrino JM; Doyle D; Prince R; Fardellone P; Sorensen OH; Meunier PJ
J Bone Miner Res; 2006 Apr; 21(4):536-42. PubMed ID: 16598373
[TBL] [Abstract][Full Text] [Related]
12. Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis: results of a double-blind, placebo-controlled 3-year study.
McCloskey E; Selby P; Davies M; Robinson J; Francis RM; Adams J; Kayan K; Beneton M; Jalava T; Pylkkänen L; Kenraali J; Aropuu S; Kanis JA
J Bone Miner Res; 2004 May; 19(5):728-36. PubMed ID: 15068495
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial.
Delmas PD; Ensrud KE; Adachi JD; Harper KD; Sarkar S; Gennari C; Reginster JY; Pols HA; Recker RR; Harris ST; Wu W; Genant HK; Black DM; Eastell R;
J Clin Endocrinol Metab; 2002 Aug; 87(8):3609-17. PubMed ID: 12161484
[TBL] [Abstract][Full Text] [Related]
14. Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate.
Seibel MJ; Naganathan V; Barton I; Grauer A
J Bone Miner Res; 2004 Feb; 19(2):323-9. PubMed ID: 14969403
[TBL] [Abstract][Full Text] [Related]
15. The association of radiographically detected vertebral fractures with back pain and function: a prospective study.
Nevitt MC; Ettinger B; Black DM; Stone K; Jamal SA; Ensrud K; Segal M; Genant HK; Cummings SR
Ann Intern Med; 1998 May; 128(10):793-800. PubMed ID: 9599190
[TBL] [Abstract][Full Text] [Related]
16. Whom to treat? The contribution of vertebral X-rays to risk-based algorithms for fracture prediction. Results from the European Prospective Osteoporosis Study.
Kaptoge S; Armbrecht G; Felsenberg D; Lunt M; Weber K; Boonen S; Jajic I; Stepan JJ; Banzer D; Reisinger W; Janott J; Kragl G; Scheidt-Nave C; Felsch B; Matthis C; Raspe HH; Lyritis G; Póor G; Nuti R; Miazgowski T; Hoszowski K; Armas JB; Vaz AL; Benevolenskaya LI; Masaryk P; Cannata JB; Johnell O; Reid DM; Bhalla A; Woolf AD; Todd CJ; Cooper C; Eastell R; Kanis JA; O'Neill TW; Silman AJ; Reeve J
Osteoporos Int; 2006; 17(9):1369-81. PubMed ID: 16821002
[TBL] [Abstract][Full Text] [Related]
17. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group.
Chesnut CH; Silverman S; Andriano K; Genant H; Gimona A; Harris S; Kiel D; LeBoff M; Maricic M; Miller P; Moniz C; Peacock M; Richardson P; Watts N; Baylink D
Am J Med; 2000 Sep; 109(4):267-76. PubMed ID: 10996576
[TBL] [Abstract][Full Text] [Related]
18. Long-term risk of incident vertebral fractures.
Cauley JA; Hochberg MC; Lui LY; Palermo L; Ensrud KE; Hillier TA; Nevitt MC; Cummings SR
JAMA; 2007 Dec; 298(23):2761-7. PubMed ID: 18165669
[TBL] [Abstract][Full Text] [Related]
19. Back pain, disability, and radiographic vertebral fracture in European women: a prospective study.
O'Neill TW; Cockerill W; Matthis C; Raspe HH; Lunt M; Cooper C; Banzer D; Cannata JB; Naves M; Felsch B; Felsenberg D; Janott J; Johnell O; Kanis JA; Kragl G; Lopes Vaz A; Lyritis G; Masaryk P; Poor G; Reid DM; Reisinger W; Scheidt-Nave C; Stepan JJ; Todd CJ; Woolf AD; Reeve J; Silman AJ
Osteoporos Int; 2004 Sep; 15(9):760-5. PubMed ID: 15138664
[TBL] [Abstract][Full Text] [Related]
20. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy.
Van Staa TP; Laan RF; Barton IP; Cohen S; Reid DM; Cooper C
Arthritis Rheum; 2003 Nov; 48(11):3224-9. PubMed ID: 14613287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
